Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT02489448 2022-10-26

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Phase 1/2 Completed

68 enrolled 9 charts

Breast

Breast Neoplasms

NCT01975831 2022-10-12

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Phase 1 Completed

104 enrolled 23 charts

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT03167619 2022-09-13

DORA

Phase 2 Completed

45 enrolled 19 charts

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02563925 2022-08-03

Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

Phase NA Completed

28 enrolled 9 charts

Breast

Breast Neoplasms

NCT03874325 2022-05-31

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Phase 2 Terminated

17 enrolled 10 charts

Breast

Breast Neoplasms

NCT02536794 2022-05-17

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

Phase 2 Completed

30 enrolled 18 charts

Breast

Breast Neoplasms

NCT02403271 2019-01-03

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Phase 1/2 Completed

124 enrolled 17 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms

NCT02669914 2018-11-06

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Phase 2 Terminated

4 enrolled 12 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Clinical Trials

AMTEC IIT: Phase 2 Multiarm Study in TNBC

BEGONIA

MEDIOLA

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

Study of Tremelimumab in Patients With Advanced Solid Tumors

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

DORA

Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors